Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024

Publication date: Available online 23 December 2020Source: European UrologyAuthor(s): Johann de Bono, Maha Hussain, Jinyu Kang
Source: European Urology - Category: Urology & Nephrology Source Type: research